Date published: 2025-12-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

GPR35 Inhibitors

GPR35 inhibitors, as a class, encompass a variety of compounds that indirectly modulate the function of GPR35, a G protein-coupled receptor involved in diverse biological processes. These inhibitors act primarily by targeting signaling pathways and molecular processes that are downstream or closely related to GPR35 activation. The inhibitors range from broad-spectrum kinase inhibitors like Staurosporine, which can influence multiple signaling cascades potentially linked to GPR35, to more specific pathway inhibitors such as LY294002 and Wortmannin, which target the PI3K/Akt pathway. In addition to these, MEK inhibitors like U0126 and PD98059 are included due to their role in modulating the MAPK/ERK pathway, a signaling cascade that can be affected by GPR35 activation. Similarly, mTOR inhibitor Rapamycin and p38 MAPK inhibitor SB203580 are considered for their potential impact on cellular processes downstream of GPR35. The inclusion of inhibitors targeting JNK (SP600125), protein kinase C (Go 6983), and ROCK (Y-27632) further exemplifies the diverse range of signaling mechanisms that could be influenced by GPR35 activity. Additionally, compounds like BIM 23056 and GW5074 are considered for their potential to modulate related G protein-coupled receptor functions and associated signaling pathways.

SEE ALSO...

Items 1 to 10 of 13 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

ML 145

1164500-72-4sc-361254
sc-361254A
10 mg
50 mg
$225.00
$930.00
(0)

ML 145 acts as a selective GPR35 modulator, exhibiting unique binding characteristics that enhance receptor affinity. Its structure allows for specific hydrophobic interactions with the receptor's binding pocket, promoting conformational changes that activate downstream signaling pathways. The compound's ability to stabilize receptor dimers may influence GPR35's role in various cellular processes. Additionally, its kinetic profile suggests a rapid onset of action, making it a compelling candidate for further exploration in receptor biology.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

A broad-spectrum kinase inhibitor, may affect downstream signaling pathways of GPR35.

CID 2745687

264233-05-8sc-362725
sc-362725A
10 mg
50 mg
$200.00
$800.00
1
(0)

CID 2745687 serves as a selective modulator of GPR35, characterized by its unique ability to engage in specific electrostatic interactions with the receptor. This compound promotes distinct conformational shifts that facilitate the activation of intracellular signaling cascades. Its structural features enable it to influence receptor oligomerization, potentially altering GPR35's functional dynamics. The compound's interaction kinetics indicate a nuanced engagement with the receptor, suggesting a complex regulatory role in cellular signaling networks.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

PI3K inhibitor, can modulate pathways downstream of GPR35 activation.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

Inhibits MEK, a part of the MAPK/ERK pathway, potentially influencing GPR35-related signaling.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

Another MEK inhibitor, could impact MAPK/ERK pathway associated with GPR35 signaling.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Inhibits PI3K, could affect PI3K/Akt pathway activated by GPR35.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

mTOR inhibitor, can influence downstream effects of GPR35 activation.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

p38 MAPK inhibitor, may modulate stress response pathways related to GPR35.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibits JNK, potentially affecting signaling pathways involving GPR35.